Literature DB >> 23280793

Laminin alpha 2 enables glioblastoma stem cell growth.

Justin D Lathia1, Meizhang Li, Peter E Hall, Joseph Gallagher, James S Hale, Qiulian Wu, Monica Venere, Emily Levy, M R Sandhya Rani, Ping Huang, Eunnyung Bae, Julia Selfridge, Lin Cheng, Hacer Guvenc, Roger E McLendon, Ichiro Nakano, Andrew E Sloan, Heidi S Phillips, Albert Lai, Candece L Gladson, Markus Bredel, Shideng Bao, Anita B Hjelmeland, Jeremy N Rich.   

Abstract

OBJECTIVE: Glioblastomas (GBMs) are lethal cancers that display cellular hierarchies parallel to normal brain. At the apex are GBM stem cells (GSCs), which are relatively resistant to conventional therapy. Interactions with the adjacent perivascular niche are an important driver of malignancy and self-renewal in GSCs. Extracellular matrix (ECM) cues instruct neural stem/progenitor cell-niche interactions, and the objective of our study was to elucidate its composition and contribution to GSC maintenance in the perivascular niche.
METHODS: We interrogated human tumor tissue for immunofluorescence analysis and derived GSCs from tumor tissues for functional studies. Bioinformatics analyses were conducted by mining publicly available databases.
RESULTS: We find that laminin ECM proteins are localized to the perivascular GBM niche and inform negative patient prognosis. To identify the source of laminins, we characterized cellular elements within the niche and found that laminin α chains were expressed by nonstem tumor cells and tumor-associated endothelial cells (ECs). RNA interference targeting laminin α2 inhibited GSC growth and self-renewal. In co-culture studies of GSCs and ECs, laminin α2 knockdown in ECs resulted in decreased tumor growth.
INTERPRETATION: Our studies highlight the contribution of nonstem tumor cell-derived laminin juxtracrine signaling. As laminin α2 has recently been identified as a molecular marker of aggressive ependymoma, we propose that the brain vascular ECM promotes tumor malignancy through maintenance of the GSC compartment, providing not only a molecular fingerprint but also a possible therapeutic target.
Copyright © 2012 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23280793      PMCID: PMC3615417          DOI: 10.1002/ana.23674

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  65 in total

1.  An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours.

Authors:  Talal M Fael Al-Mayhani; Siolian L R Ball; Jing-Wei Zhao; James Fawcett; Koichi Ichimura; Peter V Collins; Colin Watts
Journal:  J Neurosci Methods       Date:  2009-01-30       Impact factor: 2.390

2.  Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens.

Authors:  Steven M Pollard; Koichi Yoshikawa; Ian D Clarke; Davide Danovi; Stefan Stricker; Roslin Russell; Jane Bayani; Renee Head; Marco Lee; Mark Bernstein; Jeremy A Squire; Austin Smith; Peter Dirks
Journal:  Cell Stem Cell       Date:  2009-06-05       Impact factor: 24.633

3.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

4.  Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth.

Authors:  Hui Wang; Justin D Lathia; Qiulian Wu; Jialiang Wang; Zhizhong Li; John M Heddleston; Christine E Eyler; Jennifer Elderbroom; Joseph Gallagher; Jesse Schuschu; Jennifer MacSwords; Yiting Cao; Roger E McLendon; Xiao-Fan Wang; Anita B Hjelmeland; Jeremy N Rich
Journal:  Stem Cells       Date:  2009-10       Impact factor: 6.277

5.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Authors:  Zhizhong Li; Shideng Bao; Qiulian Wu; Hui Wang; Christine Eyler; Sith Sathornsumetee; Qing Shi; Yiting Cao; Justin Lathia; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

6.  TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma.

Authors:  Silvia Peñuelas; Judit Anido; Rosa M Prieto-Sánchez; Gerard Folch; Ignasi Barba; Isabel Cuartas; David García-Dorado; M Antonia Poca; Juan Sahuquillo; Jose Baselga; Joan Seoane
Journal:  Cancer Cell       Date:  2009-04-07       Impact factor: 31.743

7.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

8.  Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.

Authors:  John J P Kelly; Owen Stechishin; Andrew Chojnacki; Xueqing Lun; Beichen Sun; Donna L Senger; Peter Forsyth; Roland N Auer; Jeff F Dunn; J Gregory Cairncross; Ian F Parney; Samuel Weiss
Journal:  Stem Cells       Date:  2009-08       Impact factor: 6.277

9.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

10.  beta1 integrin maintains integrity of the embryonic neocortical stem cell niche.

Authors:  Karine Loulier; Justin D Lathia; Veronique Marthiens; Jenne Relucio; Mohamed R Mughal; Sung-Chun Tang; Turhan Coksaygan; Peter E Hall; Srinivasulu Chigurupati; Bruce Patton; Holly Colognato; Mahendra S Rao; Mark P Mattson; Tarik F Haydar; Charles Ffrench-Constant
Journal:  PLoS Biol       Date:  2009-08-18       Impact factor: 8.029

View more
  70 in total

1.  Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche.

Authors:  David W Infanger; YouJin Cho; Brina S Lopez; Sunish Mohanan; S Chris Liu; Demirkan Gursel; John A Boockvar; Claudia Fischbach
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

2.  Cerebrospinal fluid and serum IL-8, CCL2, and ICAM-1 concentrations in astrocytic brain tumor patients.

Authors:  O M Koper; J Kamińska; K Sawicki; J Reszeć; R Rutkowski; M Jadeszko; Z Mariak; V Dymicka-Piekarska; H Kemona
Journal:  Ir J Med Sci       Date:  2017-10-30       Impact factor: 1.568

3.  Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression.

Authors:  Xiuxing Wang; Briana C Prager; Qiulian Wu; Leo J Y Kim; Ryan C Gimple; Yu Shi; Kailin Yang; Andrew R Morton; Wenchao Zhou; Zhe Zhu; Elisabeth Anne Adanma Obara; Tyler E Miller; Anne Song; Sisi Lai; Christopher G Hubert; Xun Jin; Zhi Huang; Xiaoguang Fang; Deobrat Dixit; Weiwei Tao; Kui Zhai; Cong Chen; Zhen Dong; Guoxin Zhang; Stephen M Dombrowski; Petra Hamerlik; Stephen C Mack; Shideng Bao; Jeremy N Rich
Journal:  Cell Stem Cell       Date:  2018-04-05       Impact factor: 24.633

4.  Effects of NOTCH1 signaling inhibitor γ-secretase inhibitor II on growth of cancer stem cells.

Authors:  Xiaodong Ding; Changqing Ding; Fei Wang; Wenshuai Deng; Mingming Yu; Qinghai Meng; Peng Sun
Journal:  Oncol Lett       Date:  2018-09-03       Impact factor: 2.967

5.  ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor-initiating cells.

Authors:  Susobhan Sarkar; Franz J Zemp; Donna Senger; Stephen M Robbins; V Wee Yong
Journal:  Neuro Oncol       Date:  2015-02-01       Impact factor: 12.300

6.  Constitutive activation of myosin-dependent contractility sensitizes glioma tumor-initiating cells to mechanical inputs and reduces tissue invasion.

Authors:  Sophie Y Wong; Theresa A Ulrich; Loic P Deleyrolle; Joanna L MacKay; Jung-Ming G Lin; Regina T Martuscello; Musa A Jundi; Brent A Reynolds; Sanjay Kumar
Journal:  Cancer Res       Date:  2015-01-29       Impact factor: 12.701

7.  Cancer stem cells in glioma: challenges and opportunities.

Authors:  Jialiang Wang; Yufang Ma; Michael K Cooper
Journal:  Transl Cancer Res       Date:  2013-10-01       Impact factor: 1.241

8.  Dissecting and rebuilding the glioblastoma microenvironment with engineered materials.

Authors:  Kayla J Wolf; Joseph Chen; Jason Coombes; Manish K Aghi; Sanjay Kumar
Journal:  Nat Rev Mater       Date:  2019-08-16       Impact factor: 66.308

9.  Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules.

Authors:  Rutger K Balvers; Anne Kleijn; Jenneke J Kloezeman; Pim J French; Andreas Kremer; Martin J van den Bent; Clemens M F Dirven; Sieger Leenstra; Martine L M Lamfers
Journal:  Neuro Oncol       Date:  2013-09-17       Impact factor: 12.300

10.  Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.

Authors:  Shuli Xia; Bachchu Lal; Brian Tung; Shervin Wang; C Rory Goodwin; John Laterra
Journal:  Neuro Oncol       Date:  2015-08-27       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.